Edesa Biotech shares are trading higher after BARDA selected the company's drug for a U.S. funded platform trial in general acute respiratory distress syndrome.
Portfolio Pulse from Benzinga Newsdesk
Edesa Biotech shares are trading higher after BARDA selected the company's drug for a U.S. funded platform trial in general acute respiratory distress syndrome.
June 24, 2024 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edesa Biotech shares are trading higher following the selection of its drug by BARDA for a U.S. funded platform trial in general acute respiratory distress syndrome.
The selection by BARDA for a U.S. funded trial is a significant endorsement of Edesa Biotech's drug, likely leading to increased investor confidence and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100